- Biopharma News
Recipharm selected to operate new fill/finish facility in Morocco6 Jul 2021
Move is part of US$500 million five-year investment programme by Moroccan government and consortium to establish vaccine and biotherapeutic manufacturing capacity in the country
Swedish CDMO Recipharm will operate a new fill/finish factory in Morocco after signing a Memorandum of Understanding (MoU) along with the country's King Mohammad VI, the Morrocan Government and a consortium of Morocco's leading banks.
The facility will be located on a 42-hectare greenfield site near Casablanca airport and will be capable of producing approximately 300 million units once it becomes operational in 2023.
Recipharm said the factory would mirror its new fill finish line at its facility in Monts, France, but "on a larger scale."
"Our expertise and previous experience of fill finish manufacturing mens we're ideally placed to ensure successful tech transfer and high-quality operations," said Recipharm CEO, Marc Funk.
The Moroccan Government and the consortium will invest approximately $500 million over the next five years to establish capacity and capability for the manufacturing of vaccines and biotherapeutics in Morocco.
The investment will also help the African continent gain vaccine sovereignty and access to future biotherapeutics, as Morocco has ambitions to support the continent to become less dependent on western supplies for vaccines — an ambition supported by Recipharm.
Are you a supplier?
Here's what CPhI Online can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation